SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs

Small cell lung cancer (SCLC) represents about 13%–15% of all lung cancers. It has a particularly unfavorable prognosis and in about 70% of cases occurs in the advanced stage (extended disease). Three phase III studies tested the combination of immunotherapy (atezolizumab, durvalumab with or without...

Descripción completa

Detalles Bibliográficos
Autores principales: Belluomini, Lorenzo, Calvetti, Lorenzo, Inno, Alessandro, Pasello, Giulia, Roca, Elisa, Vattemi, Emanuela, Veccia, Antonello, Menis, Jessica, Pilotto, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047718/
https://www.ncbi.nlm.nih.gov/pubmed/35494084
http://dx.doi.org/10.3389/fonc.2022.840783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047718/
https://www.ncbi.nlm.nih.gov/pubmed/35494084
http://dx.doi.org/10.3389/fonc.2022.840783

Ejemplares similares